G6PD and cancer: All human cancer cells tested responded to PKI-587 treatment in a similar manner, i.e., time-dependent increases in the TRIM21 mRNA and protein levels, accompanied by decreased total G6PD levels, which are independent of p53 and MYC status (Fig. 4g).